CD14 and cancer: Since monocytic myeloid-derived suppressor cells (MDSC) have been shown to be enriched in the peripheral blood of cancer patients, we investigated the population of circulating monocytic MDSC, the other subset of MDSC enriched in HNSCC patients, characterized as CD14+HLA-DRlo/-, in HNSCC patients on the UPCI 08–013 trial, a cetuximab single agent trial in which the patients received weekly doses of cetuximab for 3 to 4 weeks before surgery [19].